Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Operating expenses:
Research and development	$ 677,151	$ 1,025,442	$ 1,767,942	$ 2,425,404
Clinical and regulatory	3,718,902	1,258,566	9,261,529	3,218,137
General and administrative	947,392	832,101	3,150,394	2,844,883
Total operating expenses	5,343,445	3,116,109	14,179,865	8,488,424
Loss from operations	(5,343,445)	(3,116,109)	(14,179,865)	(8,488,424)
Non-operating (expenses) income
Interest expense	(108,834)	(8,138)	(257,339)	(8,138)
Other income (expense)	4,449	(12,762)	29,909	(39,291)
Interest income	20,121	9,740	49,970	27,261
Total non-operating (expenses) income	(84,264)	(11,160)	(177,460)	(20,168)
Net loss	(5,427,709)	(3,127,269)	(14,357,325)	(8,508,592)
Net loss - non-controlling interest	(242,244)	(126,865)	(549,190)	(330,675)
Net loss attributable to Heat Biologics, Inc.	$ (5,185,465)	$ (3,000,404)	$ (13,808,135)	$ (8,177,917)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted	$ (0.62)	$ (0.46)	$ (1.75)	$ (1.27)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic and diluted	8,408,376	6,469,272	7,880,637	6,445,129
Other comprehensive loss:
Net loss	$ (5,427,709)	$ (3,127,269)	$ (14,357,325)	$ (8,508,592)
Unrealized loss on foreign currency translation	(27,244)		(64,238)
Total other comprehensive loss	(5,454,953)	$ (3,127,269)	(14,421,563)	$ (8,508,592)
Comprehensive loss attributable to non-controlling interest	(242,244)	(126,865)	(549,190)	(330,675)
Comprehensive loss	$ (5,212,709)	$ (3,000,404)	$ (13,872,373)	$ (8,177,917)